• About MVID
    • What is MVID?
    • Diagnosis and prevalence
    • Treatment
    • Genetics
  • Patient resources
  • Our research
  • For Doctors
  • About us
    • Who we are
    • Contact us
  • News
  • English
    • Türkçe
    • العربية
Vanessa Research, Inc. Logo Vanessa Research, Inc. Logo
  • About MVID
    • What is MVID?
    • Diagnosis and prevalence
    • Treatment
    • Genetics
  • Patient resources
  • Our research
  • For Doctors
  • About us
    • Who we are
    • Contact us
  • News
  • English
    • Türkçe
    • العربية
    September 13, 2017 - Hamden, Connecticut

    Vanessa Research, Inc. receives EU Patent for Shylicine™, a Therapy for a Rare Pediatric Disorder

    June 30, 2017 Hamden, Connecticut – Vanessa Research, Inc. (VRI), an emerging healthcare and biotech company, announced today that the European Patent Office (EPO) has issued a patent for the formulation of an oral anti-diarrheal treatment for babies and young children with Microvillus Inclusion Disease (MVID). The U.S. and world patents are pending. The formula,...
    Read more
    • « Previous Page
    • 1
    • 2

Sign up to our Newsletter

You have the right to withdraw your consent at any time. Every email we send you will include a one-click unsubscribe link so you can leave the list at any time.

About MVID

  • What is MVID?
  • Diagnosis and prevalence
  • Treatment
  • Genetics

About us

  • Who we are
  • Privacy Policy
  • Terms of use

Contact us

Please contact us via the form below. We will respond to all enquiries as quickly as possible.

Vanessa Research, Inc. Logo Vanessa Research, Inc. Logo

© 2022 Vanessa Biotech. - This web site is directed only to U.S. consumers for products
and services of Vanessa Biotech United States. This web site is not directed to consumers outside of the U.S.

Our site uses cookies and other technologies so that we, and our partners, can remember you and understand how you use our site. Access our Privacy policy, as seen on every page, to see a complete list of these technologies and to tell us whether they can be used on your device. Further use of this site will be considered consent.